Advertisement

Bronchoalveolar and Serum Markers of Lung Disease

  • Carlos M. Luna
Chapter
  • 96 Downloads

Abstract

There is no consensus at the moment on the meaning of the term marker. In this chapter the term marker is going to be used to designate any abnormality in serum or bronchoalveolar (BAL) fluid components, including the cellular composition of BAL, provided these components are not considered part of the classical criteria for disease diagnosis. Markers may be useful for studying diffuse lung disorders, in a number of ways; (1) screening of high risk individuals for the presence of disease, (2) diagnosing diseases, (3) monitoring the effectiveness of therapy, and (4) detecting recurrences or complications. Although experts agree that lung biopsy is necessary for an accurate diagnosis of most diffuse lung diseases, some markers may be specific for a particular type of disease, as Langerhans cells in bronchoalveolar lavage (BAL) in histiocytosis-X. More often, markers may be of help in the diagnosis of diseases, monitoring the effectiveness of therapy or detecting recurrences, when they are used together with clinical, radiological and laboratory data (e.g. serum angiotensin converter enzyme (ACE) in sarcoidosis or serum precipitating antibodies in hypersensitivity pneumonitis).

Keywords

Idiopathic Pulmonary Fibrosis Bronchoalveolar Lavage Interstitial Lung Disease Acute Respiratory Distress Syndrome Bronchoalveolar Lavage Fluid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Luqmani RA, Bacon PA, Beaman M et al. (1994) Classical versus non-renal Wegener’s granulomatosis. Q J Med 87: 161–7.PubMedGoogle Scholar
  2. 2.
    Crystal RG, Fulmer JD, Roberts WC et al. (1976) Idiopathic pulmonary fibrosis: clinical, histologic, radiographic, physiologic, scintigraphic, cytologic and biochemical aspects. Ann Intern Med 85: 769–88.PubMedGoogle Scholar
  3. 3.
    Winterbauer RH, Hammar SP, Hallman KO et al. (1978) Diffuse interstitial pneumonitis: Clinicopathologic correlations in 20 patients treated with prednisone/azatioprine. Am J Med 65: 661–72.PubMedCrossRefGoogle Scholar
  4. 4.
    Soergel KH, Sommers SC (1962) Idiopathic pulmonary hemosiderosis and related syndromes. Am J Med 32: 499–511.CrossRefGoogle Scholar
  5. 5.
    Hoffman RM, Rogers RM (1993) Pulmonary alveolar proteinosis. In: Bone RC, Dantzker DD, George RB, Matthay RA, Reynolds HY, Pulmonary and criti-cal care medicine. Mosby Year Book, St. Louis, vol 2, pp. M12:l–7.Google Scholar
  6. 6.
    Basset F, Corrin B, Spencer H (1978) Pulmonary his-tiocytosis X. Am Rev Respir Dis 118: 811–20.PubMedGoogle Scholar
  7. 7.
    Friedman PJ, Liebow AA, Sokoloff J (1980) Eosinophilic granuloma of the lung. Medicine (Baltimore) 60: 381–96.Google Scholar
  8. 8.
    Cormier Y, Bélanger J, Durand P (1985) Factors influencing the development of serum precipitins to farmer’s lung antigen in Quebec dairy farmers. Thorax 40: 138–42.PubMedCrossRefGoogle Scholar
  9. 9.
    Burell P, Rylander R (1981) A critical review of the role of precipitins in hypersensitivity pneumonitis. Eur J Respir Dis 62: 332–43.Google Scholar
  10. 10.
    Fink JN (1987) Epidemiologic aspects of hypersensi-tivity pneumonitis. Monogr Allergy 211: 59–69.Google Scholar
  11. 11.
    DePaso WJ, Winterbauer RH (1991) Interstitial lung disease. Disease-a-Month 38: 63–133.Google Scholar
  12. 12.
    Lakhanpal S, Lie JT, Conn DL et al. (1987) Pulmonary disease in polymyositis/dermatomyositis: A clinicopathological analysis of 65 autopsy cases. Ann Rheum Dis 46: 23–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Frazier AR, Miller RD (1974) Interstitial pneumonitis in association with polymyositis and dermatomyositis. Chest 65: 403–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Gross M, Esterly JR, Earle RH (1972) Pulmonary manifestation in systemic lupus erythematosus. Am Rev Respir Dis 105: 572–7.PubMedGoogle Scholar
  15. 15.
    Wiedemann HP, Matthay RA (1989) Pulmonary manifestations of collagen vascular diseases. Clin Chest Med 10: 577–622.Google Scholar
  16. 16.
    Hedgpeth T, Boulware BW (1988) Interstitial pneu-monitis in antinuclear antibody-negative SLE: a new clinical manifestation and possible association with anti-Ro (SSA) antibodies. Arthritis Rheum 31: 545–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Nolle B, Specks U, Ludemann J et al. (1989) Anticytoplasmatic autoantibodies: their immunodi- agnostic value in Wegener’s granulomatosis. Ann Intern Med 11: 28–40.Google Scholar
  18. 18.
    Lazaro MA, Maldonado Coco J A, Catoggio LJ et al. (1989) Clinical and serological characteristics of patients with overlap syndrome. Is mixed connective tissue disease a clinical entity? Medicine (Baltimore) 68: 58–65.CrossRefGoogle Scholar
  19. 19.
    Luna CM, Gene RJ, Jolly EC et al. (1985) Pulmonary lymphangiomyomatosis associated with tuberous sclerosis. Chest 88: 473–5.PubMedCrossRefGoogle Scholar
  20. 20.
    Zahner J, Borst MM, Wort H (1991) Treatment of lymphangioleiomyomatosis. N Engl J Med 325: 1626–32.Google Scholar
  21. 21.
    Kanbe A, Ajiro K, Adachi I, Honda K et al. (1987) Lymphangioleiomyomatosis associated with chilous ascites and high serum Ca-125 level: a case report. Jpn J Med 26: 237–42.PubMedCrossRefGoogle Scholar
  22. 22.
    Sharma OP (1990) Sarcoidosis. Disease-a-Month 36: 471–535.CrossRefGoogle Scholar
  23. 23.
    Liberman J (1975) Elevation of serum angiotensin converting enzyme in sarcoidosis. Am J Med 59: 356–62.Google Scholar
  24. 24.
    Rubin DB, Weiner-Kronish JP, Murray JF et al. (1990) Elevated von Willebrand factor antigen is an early plasma predictor of acute lung injury in non- pulmonary sepsis syndrome. J Clin Invest 86: 474–80.PubMedCrossRefGoogle Scholar
  25. 25.
    Hyers TM, Tricomy SM, Dettenmeyer PA et al. (1991) Tumor necrosis factor level in serum and bronchoalveolar lavage fluid of patients with the adults respiratory distress syndrome. Am Rev Respir Dis 144: 268–71.PubMedCrossRefGoogle Scholar
  26. 26.
    Rosenow EC, Myers IL, Swensen SJ et al. (1992) Drug-induced pulmonary disease: an update. Chest 101: 97–101.CrossRefGoogle Scholar
  27. 27.
    Thompson GP, Roberts GD (1994) An approach to diagnostic methods. In: Niederman MS, Sarosi GA, Glassroth J, eds. Respiratory infections: a scientific basis for management. WB Saunders Company, Philadelphia, pp. 489–98.Google Scholar
  28. 28.
    Lazzarotto T, Dalmonte P, Boccuni MC et al. (1992) Lack of correlation between virus detection and serologic tests for diagnosis of active cytomegalovirus infection in patients with AIDS. J Clin Microbiol 30: 1027–9.PubMedGoogle Scholar
  29. 29.
    Fahey JL, Taylor JMG, Detels RG et al. (1990) The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med 322: 166–72.PubMedCrossRefGoogle Scholar
  30. 30.
    Ramirez RJ, Kieffer RF Jr, Ball WC (1965) Bronchopulmonary lavage in man. Ann Intern Med 63: 819–28.PubMedGoogle Scholar
  31. 31.
    Schreider JP, Raabe OG (1981) Structure of the human respiratory acinus. Am J Anat 162: 221–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Hunninghake GW, Gadek JE, Kawanami O et al. (1979) Inflammatory and immune processes in the human in health and disease: evaluation by bronchoalveolar lavage. Am J Pathol 97: 149–98.PubMedGoogle Scholar
  33. 33.
    Haslam PL (1984) Bronchoalveolar lavage. Semin Resp Med 6: 55–70.CrossRefGoogle Scholar
  34. 34.
    Davis GS, Giancola MS, Constanza MC (1982) Analysis of sequential bronchoalveolar lavage samples from healthy human volunteers. Am Rev Respir Dis 126: 611–16.PubMedGoogle Scholar
  35. 35.
    Dohn MN, Baughman RP (1985) Effect of changing instilled volume from bronchoalveolar lavage in patients with interstitial lung disease. Am Rev Respir Dis 132: 390–2.PubMedGoogle Scholar
  36. 36.
    Klech H, Pohl W (1989) Use of bronchoalveolar lavage in interstitial lung disease. Technical recommendations and guidelines for bronchoalveolar lavage (BAL). Report of the European Society of Pneumology Task Group on BAL. Eur Respir J 2: 561–85.Google Scholar
  37. 37.
    Dhillon DP, Haslam PL, Townsend PJ et al. (1986) Bronchoalveolar lavage in patients with interstitial lung diseases: Side effects and factors affecting fluid recovery. Eur J Respir Dis 68: 342–50.PubMedGoogle Scholar
  38. 38.
    Patterson MW, Nugent KM, Jolles H et al. (1988) Uniformity of bronchoalveolar lavage in patients with sarcoidosis. Am Rev Respir Dis 137: 79–84.CrossRefGoogle Scholar
  39. 39.
    Garcia JGN, Wolven RG, Garcia GL et al. (1986) Assessment of interlobar variation of bronchoalveolar lavage cells differentials in interstitial lung disease. Am Rev Respir Dis 133: 444–9.PubMedGoogle Scholar
  40. 40.
    Helmers RA, Hunninghacke CW (1989) Broncho-alveolar lavage In: Wang KP, ed. Biopsy technique in pulmonary disorders, Raven Press, New York, pp. 15–28.Google Scholar
  41. 41.
    Stoller JK, Rankin JA, Reynolds HY (1987) The impact of bronchoalveolar lavage cell analysis on clinicians’ diagnostic reasoning about interstitial lung disease. Chest 80: 268–71.Google Scholar
  42. 42.
    ATS (1990) American thoracic statement: clinical role of bronchoalveolar lavage in adults with pulmonary disease. Am Rev Respir Dis 142: 481–6.Google Scholar
  43. 43.
    Watters LC, Schwarz MI, Cherniack LM et al. (1987) Idiopathic pulmonary fibrosis. Pre-treatment bron-choalveolar lavage fluid constituents and their relationship with histopathology and clinical response to therapy. Am Rev Respir Dis 135: 696–704.PubMedGoogle Scholar
  44. 44.
    Haslam PL, Turton CWG, Heard B et al. (1980) Bronchoalveolar lavage in pulmonary fibrosis: com-parison of cells obtained with lung biopsy and clinical features. Thorax 35: 8–18.Google Scholar
  45. 45.
    Haslam PL, Turton CWG, Lukozek A et al. (1980) Bronchoalveolar lavage fluid cell counts in cryptogenic fibrosing alveolitis and their relation to therapy. Thorax 35: 328–39.PubMedCrossRefGoogle Scholar
  46. 46.
    Crystal RG, Gadek JE, Ferrans VJ et al. (1981) Interstitial lung diseases: current concepts on patho-genesis, staging and therapy. Am J Med 70: 542–8.PubMedCrossRefGoogle Scholar
  47. 47.
    Turner-Warwick M, Haslam PL (1987) The value of serial bronchoalveolar lavages in assessing the clini-cal progress of patients with cryptogenic fibrosing alveolitis. Am Rev Respir Dis 92: 51–6.Google Scholar
  48. 48.
    Merril WW, Reynolds HY (1983) Bronchial lavage in inflammatory lung disease. Clin Chest Med 4: 71–84.Google Scholar
  49. 49.
    Robinson PC, Watters LC, King TE et al. (1988) Idiopathic pulmonary fibrosis: abnormalities in bronchoalveolar lavage fluid phospholipids. Am Rev Respir Dis 137: 585–91.PubMedGoogle Scholar
  50. 50.
    Basset F, Soler P, Jaurand MC et al. (1977) Ultrastructural examination of BAL for diagnosis of pulmonary histiocytosis X, preliminary report on four cases. Thorax 32: 303–6.PubMedCrossRefGoogle Scholar
  51. 51.
    Chollet S, Soler P, Doumovo P et al. (1984) Diagnosis of histiocytosis X by immunodetection of Langerhans cells in bronchoalveolar lavage fluid. Am J Pathol 115: 225–32.PubMedGoogle Scholar
  52. 52.
    Wallaert B, Aerts C, Bart F et al. (1988) Activated alveolar macrophage as a component of subclinical inflammatory alveolitis in collagen vascular diseases. Thorax 43: 24–30.PubMedCrossRefGoogle Scholar
  53. 53.
    Kahn FW, Jones JM, England DM (1987) Diagnosis of pulmonary hemorrhage in the immunocompromised host. Am Rev Respir Dis 136: 155–60.PubMedCrossRefGoogle Scholar
  54. 54.
    Costabel U, Bross KJ, Marxen J et al. (1984) T- lymphocytosis in bronchoalveolar lavage fluid of hypersensitivity pneumonitis. Chest 85: 114–18.CrossRefGoogle Scholar
  55. 55.
    Leatherman JW, Michael AF, Schwartz BA et al. (1984) Lung T cells in hypersensitivity pneumonitis. Ann Intern Med 100: 390–2.PubMedGoogle Scholar
  56. 56.
    Reynolds HY, Fulmer JD, Kazmierovski JA et al. (1977) Analysis of cellular and protein components of bronchoalveolar lavage fluid from patients with idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis. J Clin Invest 58: 165–75.CrossRefGoogle Scholar
  57. 57.
    Bjermer L, Lundgren R, Hallgren R et al. (1989) Hyaluronan and type III procollagen peptide concentrations in bronchoalveolar lavage fluid in idiopathic pulmonary fibrosis. Thorax 44: 126–31.PubMedCrossRefGoogle Scholar
  58. 58.
    Teschler H, Schmidt B, Zwang B (1989) Procollagen III peptide levels in BAL fluid in patients with hypersensitivity pneumonitis. Am Rev Respir Dis 139: A189.Google Scholar
  59. 59.
    Costabel U, Bross KJ, Guzman J et al. (1986) Predictive value of T-cell subsets for the course of pulmonary sarcoidosis. Ann N Y Acad Sei 465: 418–26.CrossRefGoogle Scholar
  60. 60.
    Winterbauer RH, Lammert J, Seiland M et al. (1993) Bronchoalveolar lavage cell populations in the diag-nosis of sarcoidosis. Chest 104: 352–61.PubMedCrossRefGoogle Scholar
  61. 61.
    Gilbert SR, Hunninghake GW (1992) Sarcoidosis. In: Baughman RP, ed. Bronchoalveolar lavage. Mosby Year Book, St. Louis; pp. 93–115.Google Scholar
  62. 62.
    Bjermer L, Back O, Ross G et al. (1986) Mast cells and lysozyme positive macrophages in bronchoalveolar lavage from patients with sarcoidosis: valuable prognosis and activity marking parameters of disease? Acta Med Scand 220: 161–6.PubMedCrossRefGoogle Scholar
  63. 63.
    Drent M, van Velsen Blad H, Diamand M et al. (1993) Relationship between presentation of sarcoidosis and T lymphocyte profile. A study in bronchoalveolar lavage fluid. Chest 104: 795–800.PubMedCrossRefGoogle Scholar
  64. 64.
    Perrin Fayole M, Pacheco Y, Harf R et al. (1981) Angiotensin converting enzyme in bronchoalveolar lavage fluid in pulmonary sarcoidosis. Thorax 34: 790–7.CrossRefGoogle Scholar
  65. 65.
    Prior C, Barbee RA, Evans PM et al. (1990) Lavage vs. serum measurement of lysozyme, angiotensin converting enzyme and other inflamatory markers in pulmonary sarcoidosis. Eur Respir J 3: 1146–54.PubMedGoogle Scholar
  66. 66.
    Pueringer RJ, Schwartz DA, Dayton CS et al. (1993) The relationship between alveolar macrophage TNF, IL-1, and PGE2, alveolitis and disease severity in sarcoidosis. Chest 103: 832–8.PubMedCrossRefGoogle Scholar
  67. 67.
    Haslam PL (1984) Bronchoalveolar lavage. Semin Respir Med 6: 55–70.CrossRefGoogle Scholar
  68. 68.
    Miller EJ, Cohen AB, Nagao S et al. (1992) Elevated levels of NAP-l/interleukin-8 are present in the air-space of patients with the adult respiratory distress syndrome and are associated with increased mortal-ity. Am Rev Respir Dis 146: 427–32.PubMedGoogle Scholar
  69. 69.
    Clark JG, Milberg JA, Steinberg KP et al. (1995) Type III procollagen peptide in the adult respiratory distress syndrome: association of increased peptide level in bronchoalveolar lavage fluid with increase risk of death. Ann Intern Med 122: 17–23.PubMedGoogle Scholar
  70. 70.
    Chastre J, Fagon JY, Soler P, et al. (1990) Broncho-alveolar lavage for rapid diagnosis of the fat embolism syndrome in trauma patients. Ann Intern Med 113: 583–8.PubMedGoogle Scholar
  71. 71.
    Silverman JF, Turner RC, West RL et al. (1989) Bronchoalveolar lavage in the diagnosis of lipoid pneumonia. Diag Cyto Pathol 5: 3–8.Google Scholar
  72. 72.
    Jolly EC, Lowenstein JA, Bellotti M et al. (1991) Alteraciones citolögicas en el lavado broncoalveolar de los pacientes en tratamiento con amiodarona. Medicina (Buenos Aires) 51: 19–25.Google Scholar
  73. 73.
    Cordier JF (1993) Cryptogenic organising pneumon-itis. Clin Chest Med 14: 677–92.PubMedGoogle Scholar
  74. 74.
    McFadden ER Jr, Gilbert IA (1992) Asthma. N Engl J Med 327: 1928–37.CrossRefGoogle Scholar
  75. 75.
    Beasley R. Roche WR, Roberts JA, Holgate ST (1989) Cellular events in the bronchi in mild asthma and after bronchial provocation. Am rev Respir Dis 139: 806–17.PubMedGoogle Scholar
  76. 76.
    Mattoli S, Mattoso VL, Soloperto M et al. (1991) Cellular and biochemical characteristics of bron-choalveolar lavage fluid in symptomatic nonallergic asthma. J Allergy Clin Immunol 87: 794–802.PubMedCrossRefGoogle Scholar
  77. 77.
    Kirby JG, Hargreave FE, Gleich GJ et al. (1987) Bronchoalveolar cell profiles of asthmatic and non- asthmatic subjects. Am Rev Respir Dis 136: 379–83.PubMedCrossRefGoogle Scholar
  78. 78.
    Gravelyn TR, Pan PM, Eschenbacher WL (1988) Mediator release in an isolated airway segment in subjects with asthma. Am Rev Respir Dis 137: 641–6.PubMedGoogle Scholar
  79. 79.
    Beasley R, Burgess C, Crane J et al. (1993) Pathology of asthma and its clinical implications. J Allergy Clin Immunol 92: 148–54.PubMedCrossRefGoogle Scholar
  80. 80.
    Coutelle C, Caplen N, Hart S et al. (1993) Gene therapy for cystic fibrosis. Arch Dis Child 68: 437–40.PubMedCrossRefGoogle Scholar
  81. 81.
    Goldstein M, Lippmann ML, Goldberg SK (1985) Usefulness of tumor markers in serum and bron-choalveolar lavage of patients undergoing fiberoptic bronchoscopy. Am Rev Respir Dis 132: 60–4.PubMedGoogle Scholar
  82. 82.
    De Diego A, Compte L, Sanchis J et al. (1991) Usefulness of carcinoembryonic antigen determination in bronchoalveolar lavage fluid. Chest 100: 1060–3.PubMedCrossRefGoogle Scholar
  83. 83.
    Merrill WW, Goodman M, Matthay RA et al. (1981) Quantitation of carcinoembryonic antigen in the lung lining fluid of normal smokers and non- smokers. Am Rev Respir Dis 123: 29–31.PubMedGoogle Scholar
  84. 84.
    Wesselius U, Dark DS, Papasian CJ (1990) Airway carcinoembryonic antigen concentrations in patients with lung cancer or chronic bronchitis. Chest 98: 393–7.Google Scholar
  85. 85.
    LeFever A, Funahashi A (1990) Elevated prostaglandin E2 level in bronchoalveolar lavage fluid of patients with bronchogenic carcinoma. Chest 98: 1397–402.PubMedCrossRefGoogle Scholar
  86. 86.
    Funahashi A, LeFever A (1992) Evaluation of prostaglandin E2 content of bronchoalveolar lavage fluid in the diagnosis of lung cancer (Abstract) Am Rev Respir Dis 145: A426.Google Scholar
  87. 87.
    De Frutos Arribas JF, Del Rio Fernandez MC etal. (1996) Carcinoma bronquioloalveolar. An Med Interna 13: 118–121.Google Scholar
  88. 88.
    Verstraeten A, Sault MC, Wallaert B et al. (1991) Metastatic prostatic adenocarcinoma diagnosed by bronchoalveolar lavage and tumour marker determ-ination. Eur Resp J 4: 1296–8.Google Scholar
  89. 89.
    Poletti V, Romagna M, Allen KA et al. (1995) Bronchoalveolar lavage in the diagnosis of disseminated lung tumors. Acta Cytol 39: 472–7.PubMedGoogle Scholar
  90. 90.
    Garofano S, Rivera MP, Stover DE (1995) The nonAIDS immunocompromised host. In: Feinsilver FH, Fein AM, eds. Textbook of bronchoscopy. Williams and Wilkins, Baltimore, pp. 242–63.Google Scholar
  91. 91.
    Salzman SH, Rosen MJ (1995) HIV infection. In: Feinsilver FH, Fein AM, eds. Textbook of broncho-scopy. Williams and Wilkins, Baltimore, pp. 264–85.Google Scholar

Copyright information

© Springer-Verlag London Limited 1999

Authors and Affiliations

  • Carlos M. Luna

There are no affiliations available

Personalised recommendations